Revusiran Designated as Orphan Drug $ALNY $XHS
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has announced the approval from FDA for the designation of Revusiran. Revusiran is a therapeutic drug for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis). View the full release here.
Revusiran Designated as Orphan Drug $ALNY $XHS Read More »